Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Copd Bronchitis
Interventions
DRUG

TPI 1020

250 mcg/caps 2 caps BID x 42 days

DRUG

Budesonide

400mcg mcg capsules- 2 capsules BID

DRUG

Placebo

2 caps BID x42 days

Trial Locations (13)

T6G2B7

University of alberta Hsopital, Edmonton

V5Z 1 M9

Vancouver Hospital Lung Center, Vancouver

L8N4A6

Firestone Institute for Respiratory Health, Hamilton

G1P 1J6

Clinique Medical Les Saules, Les Saules

J7J 2K8

Omnispec Clinical Research Inc., Mirabel

H2X2P4

Hopital Thoracique Montreal-CSUM, Montreal

H4J1C5

Hopital Sacre Coeur de Montreal, Montreal

H9R 4S3

Kells Medical Research Group, Pointe-Claire

H1S 3A9

Complexe Medicale Langelier, Saint-Léonard

J1H 1Z1

Diex Research Inc., Sherbrooke

J1H5N4

CHUS -Hopital FLEURIMONT, Sherbrooke

G1V 4G5

Centre de Cardiologie et de Pneumologie de l'Université Laval, Ste-Foy

S7N 0W8

Royal University Hospital, Saskatoon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Syntara

INDUSTRY